-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
First, Abcam was recognized for its innovative initiatives to raise the bar in the reagent industry
Professor Giovanna Roncador , Head of the Monoclonal Antibody Unit / Biotechnology Program at the Spanish National Cancer Institute ( CNIO ), Founder and Chairman of EuroMabNet , and winner of the 2022 CiteAb 'Outstanding Personal Impact' Award , said : " As a cancer scientist and Antibody engineer , I am a firm believer that advancing science and improving reagent quality go hand in hand .
Dr Alejandra Solache , Vice President of Product R&D at Abcam and winner of the 2021 CiteAb 'Outstanding Personal Impact' award , said: " It is great to see our commitment to higher standards being recognised as we continue to find new ways to break down barriers and design Setting new industry standards to improve research reproducibility .
Finally, this year CiteAb also recognized Abcam's $340 million acquisition of BioVision for its efforts to meet the industry's growing demand for high-performance, repeatable, ready-to-use assay products
The full list of Abcam 2022 winners is as follows:
Acquisition of the Year Award -- Gold Award (Acquisition of BioVision)
About Abcam plc
As a global life sciences company, Abcam is dedicated to identifying, developing and marketing high-quality biological reagents and tools that are critical to research, drug development and diagnostics
With a proprietary development platform and world-leading antibody expertise, Abcam works with numerous life science institutions to create antibody affinity reagents for drug development, in vitro diagnostics and therapeutics
Through innovative antibody affinity reagents and detection kits, Abcam is helping to advance the global understanding of biology and disease mechanisms, thereby driving the application of new treatments and improving human health
With offices in the Americas, Asia and Europe, Abcam's global service and support network is complemented by a strong team of 1,600 employees in world-leading life science research centers
For more information, please visitand.
